{"id":"W7117119520","doi":"10.1002/cpt.70156","title":"Verekitug, a Novel Antibody Antagonist to the <scp>TSLP</scp> Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial","year":2025,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Iron Ore Company (Canada)","funders":"Manchester Biomedical Research Centre; National Institute for Health and Care Research","keywords":"Clinical endpoint; Dosing; Pharmacodynamics; Pharmacokinetics; Adverse effect; Biomarker; Thymic stromal lymphopoietin; Asthma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001405987,0.001662665,0.001821988,0.0002898103,0.0003395119,0.0008924999,0.0006655501,0.00152896,0.002468449],"category_scores_gemma":[0.0007351682,0.0006546227,0.001109413,0.0002427771,0.0007826862,0.0009127959,0.0003208768,0.002427493,0.0006409422],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005346077,"about_ca_system_score_gemma":0.0007032171,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000751461,"about_ca_topic_score_gemma":0.001468593,"domain_scores_codex":[0.9996527,0.0001433311,0.00002184899,0.00007080119,0.00003623534,0.00007503077],"domain_scores_gemma":[0.9996139,0.00008106537,0.00009174056,0.00002629183,0.00002778666,0.0001592026],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9345427,0.01279743,0.001237695,0.0006049362,0.0005790799,0.0001088905,0.0001249596,0.0006292747,0.01592081,0.0001647892,0.001294343,0.03199495],"study_design_scores_gemma":[0.8507397,0.1427077,0.003337931,0.00002723453,0.0002511612,0.00007395633,0.00002847784,0.0006953517,0.001079947,0.0001002632,0.0009364009,0.00002183686],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99106,0.004154029,0.000525525,0.0004214606,0.0002092854,0.002011098,0.000525162,0.0001149091,0.0009787166],"genre_scores_gemma":[0.9878697,0.003303691,0.001362701,0.0008632204,0.0002887466,0.002701429,0.0009802361,0.00002255048,0.00260775],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002468449,"threshold_uncertainty_score":0.008257747,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05055471882173541,"score_gpt":0.432808475411597,"score_spread":0.3822537565898616,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}